Cortisol And Cardiovascular Disease Research

---

Table of Contents

1. Introduction: Why Cortisol Matters for Heart Health
2. What Is Cortisol and How Does the HPA Axis Work?
3. Does High Cortisol Increase Cardiovascular Risk? The Core Evidence
4. Cortisol and Blood Pressure: Unpacking the Research
5. Cortisol and Atherosclerosis: What the Mechanistic Data Shows
6. Measuring Cortisol in Cardiovascular Research: Blood, Urine, and Hair
7. Do Genetic Studies Support a Causal Link?
8. Cushing's Syndrome as a Natural Experiment in Cortisol Excess
9. Stress, Cortisol, and the Risk of Heart Attack or Stroke
10. Is Cortisol a Viable Cardiovascular Biomarker?
11. What Cortisol Levels Are Considered High in CVD Research?
12. 2024–2025 Updates: Where the Evidence Stands Now
13. Clinical Implications and Open Questions
14. Summary and Key Takeaways

---

Introduction: Why Cortisol Matters for Heart Health

Cardiovascular disease remains the leading cause of death globally, and researchers have long searched beyond traditional risk factors — cholesterol, blood pressure, smoking, and obesity — for additional contributors that could refine prediction and expand treatment targets. Over the past two decades, the intersection of endocrinology and cardiology has drawn increasing scientific attention, and cortisol has emerged as one of the most actively studied hormonal candidates in this space.

The relationship between cortisol cardiovascular disease research and clinical cardiology practice has historically been complicated. Cortisol is biologically plausible as a contributor to heart disease: it influences blood pressure regulation, glucose metabolism, lipid profiles, vascular inflammation, and endothelial function. Yet for years, establishing a clean, causal relationship between circulating cortisol and hard cardiovascular endpoints proved elusive. Observational studies yielded conflicting results. Mendelian randomization analyses introduced important nuance. And the heterogeneity of cortisol measurement methods — serum, urinary, salivary, and hair — made cross-study comparisons challenging.

That picture has changed considerably in recent years. A wave of well-designed prospective cohort studies, nested case-control analyses, and updated systematic reviews published between 2019 and 2025 has substantially strengthened the evidence base. Today, the question is less "does cortisol have anything to do with cardiovascular disease?" and more "how strong is the effect, through what mechanisms does it operate, and how should clinicians respond?"

This post offers a comprehensive, evidence-grounded review of cortisol and cardiovascular disease research as it stands in 2025. It is written for a cardiology research audience and covers the mechanistic pathways, the key epidemiological studies, the genetic evidence, the measurement debate, and the clinical implications. Where the evidence is strong, we will say so. Where important uncertainties remain, we will be honest about those too.

---

What Is Cortisol and How Does the HPA Axis Work?

Cortisol is a glucocorticoid steroid hormone synthesized in the adrenal cortex, primarily in the zona fasciculata. Its production is governed by the hypothalamic-pituitary-adrenal (HPA) axis, a neuroendocrine feedback system that is central to the body's response to physiological and psychological stress.

Under normal conditions, the hypothalamus releases corticotropin-releasing hormone (CRH), which signals the anterior pituitary to secrete adrenocorticotropic hormone (ACTH). ACTH then stimulates the adrenal glands to produce and release cortisol. Circulating cortisol exerts negative feedback on both the hypothalamus and pituitary, suppressing further CRH and ACTH release. This system maintains a circadian rhythm, with cortisol levels peaking shortly after waking — the so-called cortisol awakening response — and declining across the day to a nadir in the late evening.

HPA cardiovascular interactions have been recognized for some time in physiology literature. Cortisol acts on glucocorticoid receptors (GRs) that are expressed in nearly every tissue of the body, including the heart, blood vessels, kidneys, liver, and adipose tissue. Through these receptors, cortisol exerts wide-ranging metabolic and hemodynamic effects:

• Glucose metabolism: Cortisol promotes gluconeogenesis and impairs peripheral insulin sensitivity, contributing to hyperglycemia and insulin resistance when chronically elevated.
• Lipid metabolism: Chronic cortisol excess is associated with dyslipidemia, including elevated LDL cholesterol and triglycerides, and reduced HDL cholesterol.
• Blood pressure regulation: Cortisol potentiates the vasoconstrictive effects of catecholamines, upregulates angiotensin II receptors, and exerts mineralocorticoid-like effects at the kidney when present in excess, all of which can elevate systemic blood pressure.
• Inflammation: While cortisol is broadly anti-inflammatory in the short term, chronic HPA axis dysregulation can paradoxically promote a pro-inflammatory state through GR resistance and immune system recalibration.
• Endothelial function: Excess cortisol has been shown in experimental models to impair endothelium-dependent vasodilation, reduce nitric oxide bioavailability, and promote endothelial cell apoptosis.

Understanding these mechanisms is essential context for interpreting HPA cardiovascular research, because the pathways are multiple, interacting, and dose-dependent. A brief, adaptive cortisol response to acute stress serves protective functions. A chronically elevated or dysregulated cortisol pattern is a different biological situation entirely — and one with potentially serious consequences for the cardiovascular system.

---

Does High Cortisol Increase Cardiovascular Risk? The Core Evidence

This is the central question in cortisol heart disease research, and the honest answer is: the evidence is now meaningfully convergent, though not without important caveats.

The 2010 Urinary Cortisol Study

One of the most striking early findings came from a study published in 2010 examining urinary cortisol as a predictor of cardiovascular mortality. The study measured 24-hour urinary free cortisol in a community cohort and followed participants for cardiovascular events and death over a multi-year follow-up period.

The results were notable. Individuals in the highest tertile of urinary cortisol excretion had a 5.00-fold higher risk of cardiovascular death compared to those in the lower tertiles, with a 95% confidence interval of 2.02 to 12.37. The width of that confidence interval reflects the relatively modest sample size, but the magnitude of the effect was striking and drew immediate attention from the research community. A hazard ratio of that size — if real and generalizable — would place cortisol in the same order of clinical importance as some of the most established cardiovascular risk factors.

This finding helped catalyze a new wave of cortisol heart research focused on whether this association would replicate in larger, more diverse populations.

The 2019 Morning Plasma Cortisol Study

A decade later, a large prospective cohort study with nested case-control analyses published in the European Journal of Endocrinology examined morning plasma cortisol as a predictor of incident cardiovascular disease. This study was methodologically sophisticated, leveraging two nested case-control studies embedded within prospective cohorts.

The findings showed that morning plasma cortisol was associated with incident CVD, with an odds ratio of 1.28 per 1 standard deviation higher cortisol level. The study also employed Mendelian randomization methodology, which we discuss in detail in a later section. The authors concluded that morning plasma cortisol may represent a causal cardiovascular risk factor — a claim that, if supported by genetic evidence, would have significant implications for risk stratification and potentially for intervention strategies.

This paper has become one of the most-cited sources in cortisol cardiovascular risk literature and continues to be referenced in reviews published as recently as 2025.

The 2021 AHA Cohort Summary

Perhaps one of the most clinically communicable findings in recent cortisol cardiac research came from an American Heart Association-covered study that examined cortisol and other stress hormones in relation to cardiovascular events and hypertension over a long follow-up period.

Key findings from this research included:

• Every doubling of cortisol was associated with a 90% increased risk of cardiovascular events over a median follow-up of 11.2 years.
• A doubling in the concentration of four stress hormones combined was linked to a 21 to 31% higher risk of developing hypertension over a 6.5-year follow-up period.

The 90% increase in cardiovascular event risk associated with a cortisol doubling is an effect size that demands clinical attention. Even if there is some residual confounding — as there almost always is in observational studies of stress-related biomarkers — an effect of that magnitude is unlikely to be entirely artifactual.

The 2021 Serum Cortisol Cohort Study

A separate 2021 cohort study examined serum cortisol in relation to cardiovascular risk profiles and hard cardiovascular endpoints. This study found that serum cortisol was associated with an adverse cardiovascular risk profile, including higher rates of metabolic risk factors, but was not significantly associated with coronary artery disease or acute coronary syndrome as independent endpoints.

This is an important nuance. The association between cortisol and risk factor burden does not automatically translate to an independent association with hard clinical endpoints in all study designs. The heterogeneity of findings across studies — some showing strong associations with mortality and events, others finding associations only with risk factors — likely reflects differences in study population, cortisol measurement method, follow-up duration, and statistical adjustment.

---

Cortisol and Blood Pressure: Unpacking the Research

Cortisol blood pressure research represents one of the more mechanistically grounded areas of the cortisol-CVD literature, because the pathways connecting the two are relatively well characterized.

Mechanistic Pathways

At physiological concentrations, cortisol has limited direct mineralocorticoid activity because the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) converts cortisol to inactive cortisone in mineralocorticoid-sensitive tissues, protecting aldosterone receptors. However, when cortisol is chronically elevated — as in states of HPA axis dysregulation, psychological stress, or frank hypercortisolism — this protective mechanism can be overwhelmed. The resulting mineralocorticoid receptor activation at the kidney promotes sodium retention, volume expansion, and blood pressure elevation.

Additionally, cortisol sensitizes vascular smooth muscle and the vasomotor endothelium to catecholamines. This means that in the context of elevated cortisol, the cardiovascular response to norepinephrine and epinephrine is amplified. The result is a vasopressor effect that contributes to both resting hypertension and exaggerated blood pressure reactivity to stress.

Cortisol also influences the renin-angiotensin-aldosterone system (RAAS) by upregulating angiotensin II receptor expression in vascular tissue, further augmenting vasoconstriction and blood pressure.

Epidemiological Evidence

The 2021 AHA-covered cohort data mentioned above specifically documented a 21 to 31% higher risk of incident hypertension associated with a doubling of stress hormone concentrations including cortisol, over a 6.5-year follow-up. This is consistent with multiple smaller studies that have found correlations between morning cortisol levels, urinary cortisol excretion, and resting blood pressure.

Cross-sectional data have been less consistent, partly because blood pressure and cortisol both fluctuate considerably across the day and are influenced by many of the same confounders. Prospective data, which can account for baseline blood pressure and follow participants forward, are more informative.

Several studies examining populations under chronic psychosocial stress — including work stress, caregiving burden, and socioeconomic adversity — have found that elevated cortisol partially mediates the relationship between chronic stress exposure and hypertension. This positions cortisol not merely as a correlate of blood pressure but as a biological mechanism linking stress experience to vascular outcomes.

Relevance to Clinical Risk Assessment

From a clinical standpoint, the cortisol-blood pressure relationship suggests that patients with persistently elevated cortisol — whether due to chronic stress, HPA axis dysregulation, subclinical hypercortisolism, or other causes — may be at elevated risk for developing hypertension and its downstream consequences, including left ventricular hypertrophy, renal damage, and increased stroke and MI risk. Whether screening for cortisol in hypertensive patients should become routine practice remains an open question, but the mechanistic and epidemiological data support continued investigation.

---

Cortisol and Atherosclerosis: What the Mechanistic Data Shows

Cortisol atherosclerosis research examines whether elevated cortisol promotes the development or progression of arterial plaque. The mechanistic case is plausible through several interconnected pathways.

Dyslipidemia and Insulin Resistance

Chronic cortisol excess promotes a dyslipidemic profile — elevated LDL cholesterol, elevated triglycerides, reduced HDL cholesterol — that is directly atherogenic. Elevated LDL and oxidized LDL are primary drivers of foam cell formation and plaque deposition in arterial walls. Cortisol-driven insulin resistance further elevates circulating glucose and triglycerides, compounding the atherogenic milieu.

Visceral adiposity, which is strongly promoted by glucocorticoid excess, is itself an independent contributor to atherosclerosis through the release of pro-inflammatory adipokines including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). These cytokines drive endothelial dysfunction, smooth muscle proliferation, and macrophage activation — all core processes in atherogenesis.

Endothelial Dysfunction

The vascular endothelium is a primary target of glucocorticoid signaling. High cortisol concentrations have been shown to reduce endothelial nitric oxide synthase (eNOS) expression and activity, decreasing nitric oxide (NO) availability. Since NO is the principal mediator of endothelium-dependent vasodilation and also exerts anti-inflammatory and anti-thrombotic effects at the vessel wall, its reduction is pro-atherogenic. Experimental studies in human endothelial cell cultures and animal models consistently show impaired endothelial function in response to excess glucocorticoid exposure.

Inflammatory Mechanisms

The relationship between cortisol and inflammation in the context of atherosclerosis is paradoxical. While cortisol is broadly immunosuppressive and anti-inflammatory in the short term, the chronic HPA axis dysregulation that characterizes long-standing psychological stress or subclinical hypercortisolism can produce a state of glucocorticoid resistance. In this state, immune cells become less sensitive to the anti-inflammatory signals of cortisol, and systemic inflammatory markers — particularly high-sensitivity C-reactive protein (hsCRP) — remain elevated. Since vascular inflammation is a cornerstone of atherosclerosis, this glucocorticoid resistance hypothesis provides a mechanism by which chronic stress exposure could accelerate arterial disease even when acute cortisol levels appear normal.

Direct Evidence

Direct imaging data on cortisol and atherosclerosis in humans are relatively limited but growing. Studies examining carotid intima-media thickness (CIMT) — a subclinical marker of atherosclerosis — as a function of cortisol levels have produced mixed results, with some showing positive associations and others finding no significant relationship after adjustment. The heterogeneity of these findings likely reflects the complexity of cortisol measurement and the multiple confounders inherent in observational studies of atherosclerosis.

The 2025 PMC review "Serum Cortisol and Cardiovascular Disease Risk" specifically noted associations between cortisol and metabolic syndrome — a clustering of atherogenic risk factors including central obesity, insulin resistance, dyslipidemia, and hypertension — suggesting that cortisol's contribution to atherosclerosis may operate substantially through risk factor intermediaries rather than through direct vascular effects alone.

---

Measuring Cortisol in Cardiovascular Research: Blood, Urine, and Hair

One of the most important methodological challenges in cortisol heart disease evidence research is the lack of a single, universally accepted cortisol measurement approach. Different biomarkers capture different aspects of cortisol biology, and the choice of measurement method has a direct impact on study results and their clinical interpretability.

Serum/Plasma Cortisol

Morning fasting plasma or serum cortisol is the most commonly used measurement in clinical practice and much of the research literature. It reflects the total circulating cortisol concentration at a single time point, including both protein-bound cortisol (primarily bound to corticosteroid-binding globulin, or CBG) and the biologically active free fraction.

Advantages: Standardized collection protocols, well-validated assays, widely available.

Limitations: Highly sensitive to the exact time of collection, acute stress at the time of blood draw, and CBG levels (which are altered by liver disease, pregnancy, and oral contraceptives). A single morning measurement captures only a snapshot of cortisol activity and may not reflect chronic exposure or diurnal dysregulation.

The 2019 European Journal of Endocrinology study relied on morning plasma cortisol and found an OR of 1.28 per 1 SD increase in CVD risk. The 2025 review in PMC also primarily used serum cortisol data and concluded that there is strong evidence for a cortisol–CVD relationship, with cortisol discussed as a potential biomarker for risk stratification.

Urinary Free Cortisol

24-hour urinary free cortisol (UFC) measures the amount of unbound, biologically active cortisol excreted by the kidneys over a full day. It integrates cortisol exposure across the entire 24-hour period and is less affected by time-of-day variation.

Advantages: Represents integrated daily free cortisol output; less susceptible to acute stress artifacts.

Limitations: Requires careful 24-hour urine collection, which introduces collection errors; does not capture information about cortisol dynamics (e.g., the diurnal pattern or cortisol awakening response); only elevated UFC in frank hypercortisolism, may miss subtle cortisol excess.

The landmark 2010 study that reported a 5.00-fold higher risk of cardiovascular death in the highest tertile of urinary cortisol used UFC, which partially explains why its findings were so striking — it captured integrated cortisol burden rather than a single time-point measurement.

Hair Cortisol

Hair cortisol concentration (HCC) represents the most recently developed measurement approach and reflects cumulative cortisol exposure over weeks to months, depending on hair length. Cortisol is deposited in hair as it grows (approximately 1 cm per month), so a 3 cm segment reflects roughly three months of integrated systemic cortisol exposure.

Advantages: Captures long-term cortisol exposure without the variability of acute measurements; non-invasive; retrospective assessment is possible.

Limitations: Influenced by hair treatment (dyeing, bleaching, heat), race and hair type differences in cortisol deposition, and methodological variation across laboratories. Not yet standardized for clinical use.

Several cardiovascular studies have used HCC, and it has been notably useful in stress research contexts where the goal is to assess chronic, sustained HPA axis activation rather than acute or short-term cortisol.

Salivary Cortisol

Salivary cortisol measures the free (unbound) fraction of cortisol in saliva and is particularly useful for assessing the cortisol awakening response (CAR) and diurnal variation patterns. It correlates closely with free serum cortisol.

Advantages: Non-invasive; can be collected multiple times per day to assess diurnal rhythms; measures biologically active free cortisol; suitable for ambulatory research.

Limitations: Susceptible to contamination from food, blood in saliva, and incorrect collection timing; not yet standard in large epidemiological studies.

Implications for Research Interpretation

The diversity of measurement approaches means that findings from cortisol cardiovascular risk studies must be interpreted with the measurement method in mind. A study using morning serum cortisol is asking a different question than one using 24-hour UFC or hair cortisol. Readers comparing studies should pay close attention to which cortisol metric was used, as this substantially influences the effect sizes observed and the clinical inference drawn.

---

Do Genetic Studies Support a Causal Link?

A critical test of whether an observed association between cortisol and cardiovascular disease reflects true causation — rather than reverse causation or confounding — is the Mendelian randomization (MR) approach. MR uses genetic variants as instrumental variables: because genetic variants are assigned at conception and cannot be influenced by lifestyle, behavior, or disease status, they can provide evidence of causal direction that observational studies alone cannot.

The 2020 Bidirectional Mendelian Randomization Study

A 2020 bidirectional MR analysis examined whether genetically predicted cortisol levels were associated with a range of cardiometabolic outcomes. The findings were notably different from those of observational studies.

Genetically predicted cortisol was not significantly associated with:

• Ischemic heart disease (OR 0.98 per 1 unit increase in log-transformed cortisol, 95% CI 0.93–1.03)
• Ischemic stroke
• Type 2 diabetes
• Traditional cardiovascular risk factors

These null findings in HPA cardiovascular research using genetic instruments present an important challenge to causal interpretation. An OR of 0.98 with confidence intervals that include 1.0 is not consistent with a strong causal effect of cortisol on ischemic heart disease.

How to Reconcile Observational and MR Data

The disconnect between observational associations (sometimes large) and MR null results (close to 1.0) is a pattern seen in several areas of cardiovascular epidemiology and deserves careful interpretation rather than dismissal of either body of evidence.

Several explanations have been proposed:

1. Weak instrument bias: If the genetic variants used to predict cortisol explain only a small proportion of cortisol variance, the MR analysis may be underpowered to detect modest causal effects.

1. Cortisol complexity: Cortisol biology involves not just circulating levels but receptor sensitivity, tissue-specific 11β-HSD2 activity, diurnal dynamics, and free versus bound fractions. Genetic instruments based on germline variants that influence basal cortisol levels may not capture the aspects of cortisol dysregulation that are most cardiologically relevant.

1. Residual confounding in observational studies: The observational associations may partly reflect confounding by shared risk factors — chronic stress, sleep disorders, depression, socioeconomic adversity — that independently elevate both cortisol and cardiovascular risk.

1. Life-course effects: MR captures lifetime effects of genetically elevated cortisol, which may differ from the effects of episodic or situationally elevated cortisol in mid-to-late life.

1. Pleiotropy: Genetic variants used as instruments may influence cardiovascular risk through pathways other than cortisol, violating MR assumptions.

The 2019 prospective cohort study in the European Journal of Endocrinology also included a Mendelian randomization component and found some evidence supporting a causal relationship between morning plasma cortisol and CVD, though the effect was modest and the interpretation remained cautious.

The current scientific consensus in cortisol heart disease evidence research is that observational data provide consistent evidence of an association, MR data provide mixed evidence of causation, and the question remains open and active. Future MR studies using larger genetic consortia and improved instrumental variables may resolve this uncertainty.

---

Cushing's Syndrome as a Natural Experiment in Cortisol Excess

If chronic cortisol excess truly causes cardiovascular disease, patients with Cushing's syndrome — who have pathologically elevated cortisol by definition — should demonstrate markedly elevated cardiovascular risk. The evidence strongly supports this prediction and represents some of the most compelling available data linking hypercortisolism to cardiovascular outcomes.

Cardiovascular Profile in Cushing's Syndrome

Cushing's syndrome is characterized by a cluster of cardiometabolic abnormalities that read almost directly from the list of cortisol's known physiological actions:

• Hypertension is present in approximately 70–85% of patients with active Cushing's syndrome
• Central obesity and visceral fat accumulation are hallmark features
• Insulin resistance and type 2 diabetes occur in a substantial minority
• Dyslipidemia with elevated triglycerides and LDL
• Hypercoagulability, with elevated fibrinogen, PAI-1, and von Willebrand factor
• Left ventricular hypertrophy and diastolic dysfunction

The aggregate cardiovascular risk in Cushing's syndrome is dramatically elevated. Standardized mortality ratios in untreated active Cushing's are estimated at 2 to 5 times the expected mortality, with cardiovascular causes representing a leading contributor to excess death.

Post-Cure Cardiovascular Risk

Importantly, even after biochemical cure of Cushing's syndrome — whether by surgery, radiation, or medical therapy — residual cardiovascular risk persists for years to decades. Vascular structural changes, including arterial stiffness and carotid atherosclerosis, may not fully regress. This suggests that prolonged cortisol excess causes durable cardiovascular damage that cannot be fully reversed by normalization of cortisol alone, a finding with important implications for long-term management.

Subclinical Hypercortisolism

Between pathological Cushing's syndrome and the normal population exists a spectrum of subclinical or mild autonomous cortisol secretion, increasingly recognized in patients with adrenal incidentalomas. Studies of subclinical hypercortisolism have consistently found elevated rates of metabolic syndrome, hypertension, and early cardiovascular changes compared to patients with non-functioning adrenal adenomas. This gradient — from normal cortisol to subclinical excess to frank Cushing's — with correspondingly graded cardiovascular risk, provides compelling naturalistic evidence for a cortisol–CVD relationship.

---

Stress, Cortisol, and the Risk of Heart Attack or Stroke

One of the most common lay questions about cortisol heart research is whether chronic stress can cause a heart attack or stroke through cortisol elevation. The scientific evidence on this pathway is multilayered.

The Acute Stress Response

In the context of acute physical or emotional stress, the rapid HPA axis activation produces a sharp cortisol rise alongside sympathoadrenal catecholamine release. The cardiovascular consequences include increased heart rate, elevated blood pressure, coronary vasoconstriction, platelet activation, and increased coagulability. In individuals with pre-existing coronary artery disease, this acute hemodynamic stress can precipitate plaque rupture, coronary vasospasm, or acute thrombosis — the events that typically cause myocardial infarction.

This mechanism explains the well-documented phenomenon of increased MI incidence in the hours following intense emotional events (grief, anger, fear) and natural disasters. Cortisol participates in this acute response, though catecholamines are the primary acute mediators.

Chronic Stress and Sustained Cortisol Elevation

The chronic stress pathway to cardiovascular disease operates more slowly but potentially more broadly. Persistent psychosocial stressors — work demands, relationship conflict, financial insecurity, social isolation, discrimination, caregiving burden — are associated with chronically elevated or dysregulated cortisol output, particularly elevated evening cortisol and blunted diurnal variation.

This chronic cortisol dysregulation, over months to years, promotes the intermediate risk factors described throughout this post: hypertension, dyslipidemia, insulin resistance, visceral adiposity, endothelial dysfunction, and pro-inflammatory states. Through these pathways, chronic stress exposures translate into elevated long-term cardiovascular risk.

The 2021 AHA cohort data showing a 90% higher cardiovascular event rate with a doubling of cortisol over 11.2 years of follow-up is particularly relevant here. An 11-year follow-up is long enough to capture the chronic accumulation of cortisol-driven risk factor burden and its eventual manifestation as clinical events.

The Role of Allostatic Load

The concept of allostatic load — the cumulative biological burden imposed by chronic stress and its associated neuroendocrine, immune, and metabolic dysregulation — provides a useful framework for understanding how cortisol contributes to cardiovascular disease in the context of a broader stress biology. Cortisol is one of several stress biomarkers, including epinephrine, norepinephrine, DHEA-S, and inflammatory markers, that together index allostatic load. Composite measures of allostatic load have shown stronger and more consistent cardiovascular risk associations than cortisol alone, suggesting that cortisol operates within a broader biological stress response rather than as an isolated risk factor.

---

Is Cortisol a Viable Cardiovascular Biomarker?

The question of whether cortisol should be incorporated into clinical cardiovascular risk stratification is one of the most practically important in this field. The 2025 PMC review "Serum Cortisol and Cardiovascular Disease Risk" specifically discussed cortisol as a potential biomarker and linked it to metabolic syndrome, concluding that the evidence supports a strong relationship between cortisol levels and CVD risk.

Criteria for a Useful Cardiovascular Biomarker

For cortisol to function usefully as a cardiovascular biomarker, it should:

1. Demonstrate consistent, independent association with cardiovascular outcomes across populations and study designs
2. Add predictive value beyond established risk factor models (e.g., Framingham, SCORE, ASCVD)
3. Be measurable reproducibly with standardized, accessible assays
4. Guide clinical action — either through targeted intervention or risk stratification that changes management

Current Evidence Assessment

On the first criterion, the evidence is relatively strong. Multiple prospective cohort studies, including the 2010 urinary cortisol study, the 2019 morning plasma cortisol study, and the 2021 AHA cohort data, consistently report elevated cardiovascular risk with higher cortisol levels. The 2025 PMC review adds further systematic support.

On the second criterion — incremental predictive value beyond established risk factors — the evidence is less mature. Most studies have not formally assessed whether cortisol improves the C-statistic or net reclassification index when added to standard risk models. This is a significant evidence gap.

On the third criterion, cortisol measurement is hampered by the methodological challenges discussed earlier. Morning plasma cortisol is technically accessible but sensitive to timing and acute stress artifacts. No single cortisol measurement has been validated as the optimal biomarker for cardiovascular risk.

On the fourth criterion — whether knowing cortisol levels would change management — the evidence is weakest. There are currently no randomized controlled trials demonstrating that cortisol-directed interventions in otherwise-healthy individuals reduce cardiovascular events. Interventions that lower cortisol (e.g., mindfulness-based stress reduction, pharmacological cortisol antagonists) have shown effects on intermediate biomarkers but not on hard cardiovascular endpoints.

Conclusion on Biomarker Status

Cortisol is not yet ready for routine clinical use as a standalone cardiovascular biomarker. However, the accumulating evidence justifies its continued investigation in this context, particularly in populations with chronic stress exposure, HPA axis dysfunction, or metabolic syndrome. The 2025 literature review's conclusion — that cortisol shows promise as a biomarker linked to metabolic syndrome and CVD risk — aligns with this assessment.

---

What Cortisol Levels Are Considered High in Cardiovascular Studies?

A practical question for clinicians engaging with cortisol cardiovascular risk research is: what cortisol levels were actually associated with elevated risk in the key studies, and how do they relate to clinical reference ranges?

Laboratory Reference Ranges

Standard laboratory reference ranges for morning serum cortisol (collected between 7–9 AM after overnight fast) typically fall in the range of 138 to 690 nmol/L (5 to 25 µg/dL), with considerable variation between laboratories and assay methods. Values above 690 nmol/L in a non-stressed patient raise concern for Cushing's syndrome; values below 138 nmol/L, particularly with ACTH stimulation testing, raise concern for adrenal insufficiency.

Risk Thresholds in Epidemiological Studies

The key studies in cortisol cardiac and cardiovascular risk research have generally used percentile-based or distributional thresholds rather than absolute cutoffs:

• The 2010 urinary cortisol study divided participants into tertiles of 24-hour UFC and found that the highest tertile had a 5-fold elevated cardiovascular mortality risk. The absolute UFC levels associated with this highest-risk tertile were within or only modestly above the normal reference range — suggesting that within-normal variation in cortisol output confers meaningful risk differences.

• The 2019 morning plasma cortisol study expressed risk per 1 standard deviation increase in cortisol, rather than using a specific threshold. The OR of 1.28 per SD is a continuous-variable expression of risk, meaning there is no clean cutoff above which risk becomes elevated.

• The 2021 AHA cohort used a doubling of cortisol as the unit of risk expression, finding a 90% increase in cardiovascular event risk per doubling. Again, this is a relative rather than threshold-based measure.

Clinical Implication

The lack of a single validated "high-risk" cortisol cutpoint in cardiovascular research reflects the reality that cortisol's cardiovascular effects appear to operate along a continuous gradient rather than as a categorical risk. This is actually consistent with how many cardiovascular risk factors behave — blood pressure and LDL cholesterol, for example, also confer graded rather than threshold risks.

From a practical standpoint, patients with morning cortisol in the upper quartile of the normal range, particularly when accompanied by clinical features of HPA axis dysregulation (disrupted sleep, central obesity, metabolic syndrome, chronic stress), may warrant closer cardiovascular surveillance and attention to stress-related risk factor management — even in the absence of frank hypercortisolism.

---

2024–2025 Updates: Where the Evidence Stands Now

The most recent published evidence on cortisol cardiovascular disease continues to strengthen the association and expands the mechanistic and biomarker discussions.

2025 PMC Review: Serum Cortisol and Cardiovascular Disease Risk

This comprehensive review, published in 2025 in PubMed Central, synthesized available evidence on serum cortisol as a predictor of cardiovascular disease risk. Its key conclusions included:

• The evidence supports a strong relationship between cortisol levels and CVD risk
• Cortisol is discussed as a potential biomarker for cardiovascular risk stratification
• Cortisol excess is closely linked to metabolic syndrome, providing a plausible pathway to cardiovascular disease through intermediate metabolic risk factors
• The review reinforces the importance of addressing cortisol and HPA axis dysregulation in comprehensive cardiovascular risk management

This review represents one of the most up-to-date syntheses of the field and aligns with the trajectory of HPA cardiovascular research over the preceding decade.

2025 Study: Higher Cortisol and Reduced Triiodothyronine in Cardiovascular Patients

A 2025 PMC study specifically examined hormonal profiles in cardiovascular patients and reported strong associations between elevated cortisol and increased CVD risk in this clinical population. Notably, it also found reduced circulating triiodothyronine (T3) — a thyroid hormone — in the same patients, suggesting that cortisol excess may occur within a broader hormonal dysregulation pattern in cardiovascular disease.

The co-occurrence of elevated cortisol and reduced T3 is biologically plausible: chronic illness and physiological stress suppress thyroid axis activity (the "non-thyroidal illness syndrome" or "sick euthyroid syndrome"), and cortisol itself inhibits TSH secretion and peripheral T4-to-T3 conversion. This finding opens new research directions examining the interaction between HPA and thyroid axes in cardiovascular patients.

Broader 2024–2026 Literature Trends

Updated literature and review material published from 2024 onward continue to support cortisol–CVD associations, with broader discussions encompassing:

• The role of cortisol excess in promoting hypertension and dyslipidemia as intermediate risk factors
• Growing interest in hair cortisol as a measure of chronic HPA axis activation in cardiovascular epidemiology
• Increasing attention to sleep-disordered breathing as a contributor to nocturnal cortisol elevation and cardiovascular risk
• Expanding research on stress cardiomyopathy (Takotsubo syndrome) and HPA axis dysregulation
• Interest in whether pharmacological interventions targeting the cortisol pathway — such as mifepristone (GR antagonist) or 11β-HSD1 inhibitors — might have cardiovascular protective effects in high-risk populations

The Morning Cortisol Paper's Continued Influence

The 2019 European Journal of Endocrinology study on morning plasma cortisol as a cardiovascular risk factor continues to be a key cited source in 2025 reviews and clinical discussions. Its combination of prospective cohort design and embedded Mendelian randomization — and its direct measurement of hard cardiovascular endpoints — gives it methodological credibility that sustains its influence in the literature.

---

Clinical Implications and Open Questions

What the Evidence Supports

Based on the current state of cortisol heart disease research, several conclusions are reasonably well supported:

1. Cortisol is consistently associated with cardiovascular risk across multiple study designs, sample types, and populations. The associations are not limited to extreme hypercortisolism; within-normal range variation in cortisol output appears to confer meaningful cardiovascular risk differences.

1. The effect sizes are clinically significant. A 90% increase in cardiovascular event risk per cortisol doubling, and a 5-fold increase in cardiovascular mortality in the highest urinary cortisol tertile, are not trivially small associations.

1. Mechanistic pathways are biologically plausible and multiply supported. Cortisol's effects on blood pressure, lipid metabolism, glucose homeostasis, endothelial function, and vascular inflammation each independently contribute to atherosclerosis and cardiovascular risk.

1. Cushing's syndrome provides a natural experimental model in which dramatic cortisol excess produces correspondingly dramatic cardiovascular morbidity and mortality, supporting the biological principle even where epidemiological studies show smaller effects.

1. Cortisol may be most usefully understood as a mediator of chronic stress-related cardiovascular risk, operating through intermediate metabolic and hemodynamic risk factors rather than necessarily as a direct independent cause of cardiac events.

What Remains Uncertain

1. Causal direction and independence remain incompletely resolved. The 2020 MR analysis did not support a strong causal effect of genetically predicted cortisol on ischemic heart disease, which introduces uncertainty about whether elevated cortisol causes cardiovascular disease or is primarily a correlated biomarker of shared risk exposures.

1. The optimal cortisol measurement for cardiovascular risk assessment has not been established. Morning serum, 24-hour urinary, hair, and salivary measures each capture different aspects of cortisol biology and yield different associations with cardiovascular outcomes.

1. Whether cortisol-targeting interventions reduce hard cardiovascular endpoints is not known. The therapeutic proof of principle — that lowering cortisol reduces MI, stroke, or cardiovascular mortality in at-risk individuals — has not been established in RCTs.

1. The cortisol–CVD relationship in diverse populations requires further study. Most of the key epidemiological studies were conducted in predominantly European populations, and it remains unclear whether effect sizes generalize across racial, ethnic, and socioeconomic groups.

1. The contribution of cortisol versus co-released stress hormones (DHEA, catecholamines, NPY) to cardiovascular risk is not fully disentangled. The AHA cohort data showing that composite stress hormone combinations were associated with hypertension risk suggests that cortisol may operate within a broader neuroendocrine risk profile rather than in isolation.

Clinical Recommendations Based on Current Evidence

While routine cortisol screening for cardiovascular risk stratification is not yet supported by evidence, clinicians working in cardiology and preventive medicine can reasonably:

• Consider cortisol dysregulation as part of the clinical picture in patients with metabolic syndrome, treatment-resistant hypertension, central obesity, and high chronic psychosocial stress burden
• Screen for subclinical hypercortisolism in patients with adrenal incidentalomas who also have cardiovascular risk factors
• Incorporate stress management strategies — which, among other effects, reduce HPA axis activation — into comprehensive cardiovascular risk reduction programs
• Monitor cortisol-related comorbidities (sleep disorders, depression, metabolic syndrome) in their own right as components of cardiovascular risk management
• Stay current with the evolving literature on cortisol as a biomarker, as the evidence base is developing rapidly and clinical recommendations may evolve

---

Summary and Key Takeaways

The research on cortisol and cardiovascular disease has matured considerably over the past fifteen years, moving from preliminary observations to a body of evidence that is both clinically significant and mechanistically coherent. Here is a synthesis of the most important points:

Key Findings

The association is real and robust. Multiple prospective cohort studies using different cortisol measurement methods and populations consistently report elevated cardiovascular risk in individuals with higher cortisol levels. Effect sizes range from modest (OR 1.28 per SD in the 2019 plasma cortisol study) to striking (5-fold risk in the 2010 urinary cortisol study; 90% higher event rate per cortisol doubling in the 2021 AHA cohort).

The HPA cardiovascular pathway operates through multiple intermediaries. Cortisol elevates blood pressure, promotes dyslipidemia and insulin resistance, drives visceral adiposity, impairs endothelial function, and promotes a pro-atherogenic vascular environment. These multiple converging pathways make the biological case compelling.

Cushing's syndrome provides confirmatory natural experiment data. Pathological cortisol excess produces a cardiovascular risk profile that validates the biological mechanisms inferred from epidemiological associations.

Mendelian randomization data are mixed. Genetically predicted cortisol was not significantly associated with ischemic heart disease in the 2020 bidirectional MR study (OR 0.98, 95% CI 0.93–1.03), suggesting that the causal case is not fully proven. However, methodological limitations of MR in this context mean that null genetic findings do not definitively rule out a causal effect.

Recent 2025 evidence strengthens the association. The 2025 PMC review concludes that strong evidence supports a cortisol–CVD relationship, and a 2025 study of cardiovascular patients found strong associations between elevated cortisol and increased CVD risk. The ongoing influence of the 2019 European Journal of Endocrinology study confirms morning plasma cortisol as a candidate cardiovascular risk marker.

Cortisol measurement method matters. Blood, urine, and hair cortisol each capture different aspects of cortisol biology. Study results must be interpreted in context of the measurement approach used.

Cortisol is not yet a clinical cardiovascular biomarker. Despite the strength of the observational associations, the lack of validated risk thresholds, standardized measurement protocols, and RCT evidence for cortisol-lowering interventions on hard cardiovascular endpoints prevents routine clinical application at this time.

Research Priorities

For cortisol cardiovascular risk research to progress toward clinical utility, the field needs:

• Larger, more diverse prospective cohort studies with standardized cortisol measurements and long follow-up
• More powerful Mendelian randomization analyses using larger genetic consortia and better genetic instruments
• Randomized controlled trials of cortisol-modulating interventions (pharmacological and behavioral) with hard cardiovascular endpoints
• Head-to-head comparisons of different cortisol measurement methods in the same populations
• Investigation of interaction effects between cortisol, sex hormones, thyroid function, and other cardiometabolic factors
• Studies examining whether cortisol adds incremental predictive value to existing cardiovascular risk scores

Final Perspective

The cortisol–cardiovascular disease story is one of converging evidence from multiple directions: epidemiology, mechanistic biology, genetics, and clinical medicine. While the causal proof is not airtight and clinical translation is incomplete, the accumulated weight of evidence makes it difficult to dismiss cortisol as a cardiovascular bystander. The stress-heart connection — mediated in meaningful part through the HPA axis and its primary effector hormone — is real, biologically grounded, and clinically relevant.

For cardiologists, endocrinologists, and preventive medicine specialists, this body of cortisol heart disease evidence argues for continued attention to the neuroendocrine dimensions of cardiovascular risk. Patients whose cardiovascular risk burden is driven in part by chronic HPA axis activation — whether from psychological stress, sleep disorders, socioeconomic adversity, or subclinical hypercortisolism — may represent a population in whom targeted neuroendocrine assessment and stress biology-informed management could yield meaningful clinical benefit.

The research is not finished. But what has been established is substantial, and the field is moving forward rapidly.

---

This blog post is written for a cardiology research and clinical education audience. It does not constitute medical advice. All statistics and study findings cited are based on published peer-reviewed research available as of 2025.

---

References and Data Sources Used in This Post:

1. PMC 2025 — "Serum Cortisol and Cardiovascular Disease Risk" (PMC12172220)
2. Bidirectional Mendelian Randomization Study 2020 — cortisol and cardiometabolic outcomes
3. PMC 2021 — "Associations of Serum Cortisol with Cardiovascular Risk" (PMC8041336)
4. European Journal of Endocrinology 2019 — Morning plasma cortisol as a cardiovascular risk factor (OUP, Vol 181, Issue 4)
5. American Heart Association 2021 cohort coverage — stress hormones and cardiovascular event risk
6. 2010 urinary cortisol cohort — highest tertile CVD mortality risk (HR 5.00, 95% CI 2.02–12.37)
7. PMC 2025 — "Higher cortisol level and reduced circulating triiodothyronine in cardiovascular patients"